These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15180770)

  • 1. Tolerance induction to rofecoxib in a patient with Bartter's syndrome.
    Nucera E; Schiavino D; Pollastrini E; Manna R; Di Lillo M; Buonomo A; Roncallo C; Patriarca G
    Allergy; 2004 Jul; 59(7):788-9. PubMed ID: 15180770
    [No Abstract]   [Full Text] [Related]  

  • 2. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 3. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rofecoxib and inflammatory bowel disease: clinical and pathologic observations.
    Wilcox GM; Mattia AR
    J Clin Gastroenterol; 2005 Feb; 39(2):142-3. PubMed ID: 15681911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of the VIGOR study. Rofecoxib halves the complication rate].
    MMW Fortschr Med; 2001 Jun; 143(23):35. PubMed ID: 11460417
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
    Haas NA; Nossal R; Schneider CH; Lewin MA; Ocker V; Holder M; Uhlemann F
    Pediatr Crit Care Med; 2003 Apr; 4(2):249-51. PubMed ID: 12749662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rofecoxib-induced pseudoporphyria.
    Markus R; Reddick ME; Rubenstein MC
    J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522
    [No Abstract]   [Full Text] [Related]  

  • 9. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 10. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 12. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
    van der Veen WJ; van der Werf GT
    Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 15. Psoriasis associated with rofecoxib.
    Clark DW; Coulter DM
    Arch Dermatol; 2003 Sep; 139(9):1223. PubMed ID: 12975177
    [No Abstract]   [Full Text] [Related]  

  • 16. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
    MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
    Nelson M; Cicuttini F
    Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
    MMW Fortschr Med; 2001 Jun; 143(23):34-5. PubMed ID: 11460416
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind prospective comparison of rofecoxib vs ketorolac in reducing postoperative pain after arthroscopic knee surgery.
    Kim JT; Sherman O; Cuff G; Leibovits A; Wajda M; Bekker AY
    J Clin Anesth; 2005 Sep; 17(6):439-43. PubMed ID: 16171664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.